Pfizer (NYSE:PFE) Coverage Initiated by Analysts at Mizuho

Equities research analysts at Mizuho initiated coverage on shares of Pfizer (NYSE:PFE) in a report issued on Monday, The Fly reports. The brokerage set a “buy” rating and a $38.00 price target on the biopharmaceutical company’s stock. Mizuho’s price objective points to a potential upside of 16.21% from the company’s current price.

PFE has been the topic of a number of other research reports. Cantor Fitzgerald reiterated a “buy” rating and issued a $53.00 target price on shares of Pfizer in a research note on Thursday, March 19th. Zacks Investment Research lowered Pfizer from a “buy” rating to a “hold” rating and set a $40.00 target price on the stock. in a research note on Monday, May 4th. Royal Bank of Canada reiterated a “buy” rating and issued a $44.00 target price on shares of Pfizer in a research note on Monday, April 27th. Barclays reduced their target price on Pfizer from $37.00 to $35.00 in a research note on Monday, June 1st. Finally, SVB Leerink began coverage on Pfizer in a research note on Tuesday, June 16th. They issued a “market perform” rating and a $40.00 target price on the stock. Ten equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $38.72.

Shares of PFE opened at $32.70 on Monday. The company has a market cap of $181.31 billion, a PE ratio of 11.68, a P/E/G ratio of 2.51 and a beta of 0.70. The business has a fifty day moving average of $35.60 and a 200 day moving average of $36.28. Pfizer has a 52-week low of $27.88 and a 52-week high of $44.56. The company has a quick ratio of 0.78, a current ratio of 1.02 and a debt-to-equity ratio of 0.56.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, April 28th. The biopharmaceutical company reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.09. Pfizer had a return on equity of 25.76% and a net margin of 31.17%. The business had revenue of $12.03 billion for the quarter, compared to analyst estimates of $11.38 billion. During the same quarter last year, the firm posted $0.85 earnings per share. The business’s revenue was down 8.3% compared to the same quarter last year. As a group, research analysts anticipate that Pfizer will post 2.88 earnings per share for the current fiscal year.

In other Pfizer news, EVP Douglas M. Lankler sold 65,000 shares of Pfizer stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $37.85, for a total value of $2,460,250.00. Following the transaction, the executive vice president now owns 135,375 shares in the company, valued at $5,123,943.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Jennifer B. Damico sold 2,181 shares of Pfizer stock in a transaction dated Wednesday, April 29th. The shares were sold at an average price of $38.35, for a total value of $83,641.35. Following the completion of the transaction, the senior vice president now owns 9,647 shares in the company, valued at approximately $369,962.45. The disclosure for this sale can be found here. Insiders sold 69,362 shares of company stock worth $2,622,691 in the last quarter. 0.08% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. New England Research & Management Inc. boosted its holdings in Pfizer by 17.6% in the first quarter. New England Research & Management Inc. now owns 64,809 shares of the biopharmaceutical company’s stock worth $2,115,000 after acquiring an additional 9,700 shares in the last quarter. Pathstone Family Office LLC acquired a new stake in Pfizer in the first quarter worth about $131,000. Confluence Investment Management LLC boosted its holdings in Pfizer by 4.9% in the first quarter. Confluence Investment Management LLC now owns 2,389,210 shares of the biopharmaceutical company’s stock worth $77,984,000 after acquiring an additional 112,438 shares in the last quarter. Formidable Asset Management LLC boosted its holdings in Pfizer by 8.2% in the first quarter. Formidable Asset Management LLC now owns 44,455 shares of the biopharmaceutical company’s stock worth $1,451,000 after acquiring an additional 3,365 shares in the last quarter. Finally, Seascape Capital Management boosted its holdings in Pfizer by 115.2% in the first quarter. Seascape Capital Management now owns 11,771 shares of the biopharmaceutical company’s stock worth $384,000 after acquiring an additional 6,300 shares in the last quarter. 70.28% of the stock is owned by institutional investors and hedge funds.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: How to calculate the intrinsic value of a stock

The Fly

Analyst Recommendations for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.